Clinical Trials

Currently we are performing clinical investigations of novel CAR-T and TIL therapies in multiple disease areas including hematological malignancies, solid tumors and inflammatory and immunological diseases.

Product	Indication	Clinical Study	NCT NUMBER(s)	PUBLICATION/PRESENTATION
C-CAR039	r/r B-NHL	Investigator-initiated trial in China	NCT04317885	ASCO 2021 Abstract ASCO 2021 Presentation ASH 2023 Paper ASH 2023 Presentation
			NCT04655677
			NCT04696432
			NCT04693676
		Phase 1b/2 trial in China	NCT05800977
		Phase 1b trial worldwide (ex-Greater China) licensed to JNJ	NCT05421663
C-CAR066	r/r B-NHL including prior CAR-T	Investigator-initiated trial in China	NCT04036019	ASCO 2021 Abstract ASCO 2021 Presentation ASH 2023 Paper ASH 2023 Poster
C-CAR066	r/r B-NHL including prior CAR-T	Phase 1b trial worldwide (ex-Greater China) licensed to JNJ	NCT05784441
C-CAR088	r/r Multiple Myeloma	Phase 1b/2 trial in China	NCT05521802
		Investigator-initiated trial in China	NCT04322292	Journal for Immunotherapy of Cancer 09/2022
			NCT03815383
			NCT03751293
			NCT04295018
C-CAR031	Hepatocellular Carcinoma (HCC)	Investigator-initiated trial in China	NCT05155189	AACR Abstract 04/2023 AACR Poster 04/2023
C-TIL051	Non Small Cell Lung Cancer (NSCLC)	Phase 1 trial US	NCT05676749